{
    "title": "113_hr3742",
    "content": "The Act titled \"Antibiotic Development to Advance Patient Treatment Act of 2013\" approves certain drugs for use in a limited patient population. The Antibiotic Development to Advance Patient Treatment Act of 2013 allows for the approval of certain antibacterial and antifungal drugs to treat a limited population of patients with unmet medical needs. The approval may rely on traditional or alternative endpoints. The Antibiotic Development to Advance Patient Treatment Act of 2013 allows for approval of antibacterial and antifungal drugs for limited patient populations based on traditional or alternative endpoints. Approval requires specific labeling and adherence to promotional material regulations. The Antibiotic Development to Advance Patient Treatment Act of 2013 allows for approval of antibacterial and antifungal drugs for limited patient populations based on traditional or alternative endpoints. Approval requires specific labeling and adherence to promotional material regulations. The Act also allows for withdrawal of limited population approval requirements if a drug is subsequently approved without limitations. The Antibiotic Development to Advance Patient Treatment Act of 2013 allows for approval of antibacterial and antifungal drugs for limited patient populations based on specific criteria. This includes fast track designation, accelerated approval, and approval for use in a limited patient population. The Act clarifies that existing standards of evidence apply to the review and approval process, and does not limit the Secretary's authority to approve products under this Act. The Antibiotic Development to Advance Patient Treatment Act of 2013 allows for approval of antibacterial and antifungal drugs for limited patient populations based on specific criteria. The Act clarifies the Secretary's authority to approve products under this Act, irrespective of final regulations. The Antibiotic Development to Advance Patient Treatment Act of 2013 clarifies references to antibacterial or antifungal drugs for serious or life-threatening conditions, now including biological products. It also updates monitoring procedures under Title III of the Public Health Service Act. The Antibiotic Development to Advance Patient Treatment Act of 2013 includes monitoring antibacterial and antifungal drug use and resistance under Title III of the Public Health Service Act. The Secretary will monitor antibacterial and antifungal drug use and resistance using the National Healthcare Safety Network or another appropriate system. Data from this monitoring will be made publicly available to improve monitoring of trends and ensure appropriate stewardship of these drugs. The Secretary will ensure appropriate stewardship of antibacterial and antifungal drugs, including those approved for limited populations. SEC. 3. Amends Section 511 of the Federal Food, Drug, and Cosmetic Act to establish susceptibility test interpretive criteria for microbial organisms. The Secretary will establish and update susceptibility test interpretive criteria for antibacterial drugs, including biological products, by using preclinical and clinical data, statistical methodologies, and other necessary evidence. Additionally, the Secretary will evaluate new or updated criteria identified by private entities quarterly. The Secretary will evaluate and publish new or updated susceptibility test interpretive criteria for antibacterial drugs from recognized organizations on the FDA website, either adopting, declining, or partially adopting them based on specific reasons. The Secretary compiles and publishes annual notices of susceptibility test interpretive criteria in the Federal Register. Any approved interpretive criterion may be recognized as a standard by the Secretary. Sponsors can seek approval based on different criteria than those adopted. The term 'qualified infectious disease product' is defined as a product designated under 505E(d). Susceptibility test interpretive criteria refer to specific values characterizing the resistance of bacteria to drugs. Section 1111 of the FDA Amendments Act of 2007 is repealed. The Secretary of Health and Human Services must report to Congress within one year of the Act's enactment. The Secretary of Health and Human Services must report to Congress on the progress of implementing section 511 of the Federal Food, Drug, and Cosmetic Act. SEC. 4. NO EFFECT ON HEALTH CARE PRACTICE. The Antibiotic Development to Advance Patient Treatment Act of 2013 does not restrict the prescribing of antibiotics by healthcare professionals or limit healthcare practice."
}